Serge Belanger
Stock Analyst at Needham
(3.39)
# 901
Out of 4,670 analysts
297
Total ratings
44.8%
Success rate
4.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Serge Belanger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Reiterates: Buy | $36 | $20.20 | +78.22% | 4 | Nov 21, 2024 | |
| CYTK Cytokinetics | Reiterates: Buy | $72 | $49.10 | +46.64% | 18 | Nov 20, 2024 | |
| OMER Omeros | Reiterates: Hold | n/a | $10.91 | - | 3 | Nov 14, 2024 | |
| LQDA Liquidia | Reiterates: Buy | $19 | $10.65 | +78.40% | 25 | Nov 14, 2024 | |
| CLSD Clearside Biomedical | Reiterates: Buy | $6 | $1.08 | +455.56% | 11 | Nov 13, 2024 | |
| XENE Xenon Pharmaceuticals | Reiterates: Buy | $60 | $41.15 | +45.81% | 11 | Nov 13, 2024 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $38 | $20.20 | +88.12% | 13 | Nov 13, 2024 | |
| HRTX Heron Therapeutics | Maintains: Buy | $5 → $4 | $1.07 | +273.83% | 19 | Nov 13, 2024 | |
| RVNC Revance Therapeutics | Reiterates: Hold | n/a | $3.73 | - | 20 | Nov 8, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $22 | $17.55 | +25.36% | 23 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.91 | +174.91% | 15 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.14 | +77.51% | 16 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $0.99 | - | 15 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $7.60 | +84.21% | 9 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $18 | $9.96 | +80.72% | 14 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $12.60 | +74.60% | 11 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $62 | $54.32 | +14.14% | 10 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $10.15 | +215.27% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $2.52 | +138.10% | 16 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $29.96 | - | 23 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $45.46 | - | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.88 | - | 1 | Mar 31, 2022 |
NewAmsterdam Pharma Company
Nov 21, 2024
Reiterates: Buy
Price Target: $36
Current: $20.20
Upside: +78.22%
Cytokinetics
Nov 20, 2024
Reiterates: Buy
Price Target: $72
Current: $49.10
Upside: +46.64%
Omeros
Nov 14, 2024
Reiterates: Hold
Price Target: n/a
Current: $10.91
Upside: -
Liquidia
Nov 14, 2024
Reiterates: Buy
Price Target: $19
Current: $10.65
Upside: +78.40%
Clearside Biomedical
Nov 13, 2024
Reiterates: Buy
Price Target: $6
Current: $1.08
Upside: +455.56%
Xenon Pharmaceuticals
Nov 13, 2024
Reiterates: Buy
Price Target: $60
Current: $41.15
Upside: +45.81%
Viridian Therapeutics
Nov 13, 2024
Reiterates: Buy
Price Target: $38
Current: $20.20
Upside: +88.12%
Heron Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.07
Upside: +273.83%
Revance Therapeutics
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $3.73
Upside: -
Pacira BioSciences
Nov 8, 2024
Reiterates: Buy
Price Target: $22
Current: $17.55
Upside: +25.36%
Nov 8, 2024
Reiterates: Buy
Price Target: $8
Current: $2.91
Upside: +174.91%
Nov 7, 2024
Reiterates: Buy
Price Target: $18
Current: $10.14
Upside: +77.51%
Nov 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $0.99
Upside: -
Nov 5, 2024
Reiterates: Buy
Price Target: $14
Current: $7.60
Upside: +84.21%
Oct 31, 2024
Maintains: Buy
Price Target: $10 → $18
Current: $9.96
Upside: +80.72%
Sep 13, 2024
Reiterates: Buy
Price Target: $22
Current: $12.60
Upside: +74.60%
Sep 12, 2024
Reiterates: Buy
Price Target: $62
Current: $54.32
Upside: +14.14%
Sep 6, 2024
Reiterates: Buy
Price Target: $32
Current: $10.15
Upside: +215.27%
Aug 13, 2024
Maintains: Buy
Price Target: $8 → $6
Current: $2.52
Upside: +138.10%
Aug 9, 2024
Reiterates: Hold
Price Target: n/a
Current: $29.96
Upside: -
Aug 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $45.46
Upside: -
Mar 31, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.88
Upside: -